K Roger Aoki

Summary

Affiliation: Allergan Inc
Country: USA

Publications

  1. ncbi request reprint Botulinum toxin: a successful therapeutic protein
    K Roger Aoki
    Neurotoxin Research Program, Biological Sciences, Allergan, LLC, 2525 Dupont Drive, Irvine, CA 92612, USA
    Curr Med Chem 11:3085-92. 2004
  2. doi request reprint Updates on the antinociceptive mechanism hypothesis of botulinum toxin A
    K Roger Aoki
    Discovery Research, Biological Sciences, Allergan, 2525 Dupont Drive, Irvine, CA 92612 1599, USA
    Parkinsonism Relat Disord 17:S28-33. 2011
  3. ncbi request reprint Pharmacology and immunology of botulinum toxin type A
    K Roger Aoki
    Allergan Inc, 7575 Dupont Drive, Irvine, CA 92612, USA
    Clin Dermatol 21:476-80. 2003
  4. ncbi request reprint Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A
    K R Aoki
    Department of Biological Sciences RD 2C, Allergan, Inc, Irvine, CA 92623, USA
    Neurotoxicology 26:785-93. 2005
  5. ncbi request reprint Using translational medicine to understand clinical differences between botulinum toxin formulations
    K R Aoki
    Department of Biological Sciences, Neurotoxin Research Program, Allergan Inc, Irvine, CA 92612 1599, USA
    Eur J Neurol 13:10-9. 2006
  6. ncbi request reprint Physiology and pharmacology of therapeutic botulinum neurotoxins
    K Roger Aoki
    Neurotoxin Research Program, Biological Sciences, Allergan Inc, Irvine, Calif, USA
    Curr Probl Dermatol 30:107-16. 2002
  7. ncbi request reprint Future aspects of botulinum neurotoxins
    K R Aoki
    Department of Biological Sciences, Allergan Inc, CA, USA
    J Neural Transm 115:567-73. 2008
  8. ncbi request reprint Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety
    K Roger Aoki
    Allergan Incorporated, 2525 Dupont Drive, Irvine, CA 92715, USA
    Toxicon 40:923-8. 2002
  9. ncbi request reprint Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions
    K R Aoki
    Allergan, Inc, Irvine, CA 92715, USA
    Eur J Neurol 8:21-9. 2001
  10. ncbi request reprint A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice
    K R Aoki
    Allergan, Inc, 2525 Dupont Drive, Irvine, CA 92715, USA
    Toxicon 39:1815-20. 2001

Collaborators

Detail Information

Publications34

  1. ncbi request reprint Botulinum toxin: a successful therapeutic protein
    K Roger Aoki
    Neurotoxin Research Program, Biological Sciences, Allergan, LLC, 2525 Dupont Drive, Irvine, CA 92612, USA
    Curr Med Chem 11:3085-92. 2004
    ..g. botulism). This review will focus on the current understanding of the mechanism of action of botulinum neurotoxins and the pharmacology of the various approved-marketed products and the direction of future research...
  2. doi request reprint Updates on the antinociceptive mechanism hypothesis of botulinum toxin A
    K Roger Aoki
    Discovery Research, Biological Sciences, Allergan, 2525 Dupont Drive, Irvine, CA 92612 1599, USA
    Parkinsonism Relat Disord 17:S28-33. 2011
    ..This review summarizes the literature to update the hypothesis for the mechanism by which botulinum toxin type A can modulate chronic pain...
  3. ncbi request reprint Pharmacology and immunology of botulinum toxin type A
    K Roger Aoki
    Allergan Inc, 7575 Dupont Drive, Irvine, CA 92612, USA
    Clin Dermatol 21:476-80. 2003
    ....
  4. ncbi request reprint Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A
    K R Aoki
    Department of Biological Sciences RD 2C, Allergan, Inc, Irvine, CA 92623, USA
    Neurotoxicology 26:785-93. 2005
    ..Through this mechanism, BOTOX inhibits peripheral sensitization in these models, which leads to an indirect reduction in central sensitization...
  5. ncbi request reprint Using translational medicine to understand clinical differences between botulinum toxin formulations
    K R Aoki
    Department of Biological Sciences, Neurotoxin Research Program, Allergan Inc, Irvine, CA 92612 1599, USA
    Eur J Neurol 13:10-9. 2006
    ....
  6. ncbi request reprint Physiology and pharmacology of therapeutic botulinum neurotoxins
    K Roger Aoki
    Neurotoxin Research Program, Biological Sciences, Allergan Inc, Irvine, Calif, USA
    Curr Probl Dermatol 30:107-16. 2002
  7. ncbi request reprint Future aspects of botulinum neurotoxins
    K R Aoki
    Department of Biological Sciences, Allergan Inc, CA, USA
    J Neural Transm 115:567-73. 2008
    ..Unfortunately, the future of BoNTs will also likely include attempts to obtain and distribute unlicensed and illegal BoNT products that may pose substantial risks to patients...
  8. ncbi request reprint Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety
    K Roger Aoki
    Allergan Incorporated, 2525 Dupont Drive, Irvine, CA 92715, USA
    Toxicon 40:923-8. 2002
    ..The in vivo differences found are consistent with the different clinical profiles reported for these two products...
  9. ncbi request reprint Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions
    K R Aoki
    Allergan, Inc, Irvine, CA 92715, USA
    Eur J Neurol 8:21-9. 2001
    ..As demonstrated in preclinical and clinical studies, these differences result in a unique combination of efficacy, duration of action, safety, and antigenic potential for each botulinum neurotoxin preparation...
  10. ncbi request reprint A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice
    K R Aoki
    Allergan, Inc, 2525 Dupont Drive, Irvine, CA 92715, USA
    Toxicon 39:1815-20. 2001
    ..8+/-1.1, respectively). Thus, the BTX preparations exhibited different safety margins in mice. These results support the hypothesis that the preparations are unique therapeutics and are not interchangeable based on a simple dose ratio...
  11. pmc Plasma membrane localization signals in the light chain of botulinum neurotoxin
    Ester Fernandez-Salas
    Neurotoxin Research Program, Department of Biological Sciences, Allergan Inc, 2525 Dupont Drive, Irvine, CA 92612 1599, USA
    Proc Natl Acad Sci U S A 101:3208-13. 2004
    ..These data support sequence-specific signals as determinants of intracellular localization and as a basis for the different durations of action in these two BoNT serotypes...
  12. ncbi request reprint Pharmacology and immunology of botulinum toxin serotypes
    K R Aoki
    Allergan, Inc, Irvine, CA 92623, USA
    J Neurol 248:3-10. 2001
    ..Differences in formulations or serotypes impart unique efficacy and safety profiles and thus does not support a simple dose ratio conversion between products...
  13. ncbi request reprint Is the light chain subcellular localization an important factor in botulinum toxin duration of action?
    Ester Fernandez-Salas
    Neurotoxin Research Program, Department of Biological Sciences, Allergan Inc, Irvine, California 92612, USA
    Mov Disord 19:S23-34. 2004
    ....
  14. ncbi request reprint Evidence for antinociceptive activity of botulinum toxin type A in pain management
    K Roger Aoki
    Neurotoxin Research, Biological Sciences, Allergan, Irvine, Calif, USA
    Headache 43:S9-15. 2003
    ..Further research is needed to determine whether the antinociceptive mechanism mediated by botulinum toxin type A affects the neuronal signaling pathways that are activated during migraine...
  15. ncbi request reprint Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution
    Diane D S Tang-Liu
    Department of Pharmacokinetics and Drug Metabolism, Allergan, Inc, 2525 Dupont Drive, RD2 2B, Irvine, CA 92715, USA
    Toxicon 42:461-9. 2003
    ..The results indicate that most of the neurotoxin does not diffuse from the injection site, whether in free or complexed form, and this may reduce the potential for systemic effects...
  16. ncbi request reprint Pharmacology and immunology of botulinum neurotoxins
    K Roger Aoki
    Neurotixins Research Program, Biological Sciences, Allergan LLC, 2525 Dupont Drive, Irvine, CA 92612, USA
    Int Ophthalmol Clin 45:25-37. 2005
  17. ncbi request reprint Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition
    K Roger Aoki
    Ailergan, Inc, Irvine, California, USA
    Crit Rev Immunol 30:167-87. 2010
    ..These constructs should be clinically useful for epitope-selective modulation of Ab responses to restore effective BoNT treatment in immunoresistant patients...
  18. ncbi request reprint Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain
    Li Zhang
    Neurotoxin Preclinical Research Program, Department of Biological Sciences, Allergan Inc, 2525 Dupont Drive, Irvine, CA 92612, USA
    Gene 315:21-32. 2003
    ..The reported sequence information for type A-Hall strain will potentially facilitate elucidation of the toxin interactions with the nontoxin proteins in the complex...
  19. ncbi request reprint Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons
    Patrick G Foran
    Centre for Neurobiochemistry, Department of Biological Sciences, Imperial College, London SW7 2AZ, United Kingdom
    J Biol Chem 278:1363-71. 2003
    ..These novel findings could aid development of new toxin therapies for patients resistant to BoNT/A and effective treatments for human botulism...
  20. ncbi request reprint Botulinum toxin type A: myths, facts, and current research
    Stephen D Silberstein
    Headache 43:S1. 2003
  21. ncbi request reprint Two protein trafficking processes at motor nerve endings unveiled by botulinum neurotoxin E
    Gary Lawrence
    International Centre for Neurotherapeutics, Dublin City University, Dublin 9, Ireland
    J Pharmacol Exp Ther 320:410-8. 2007
    ..These novel observations reveal that two membrane retrieval mechanisms are operative at motor nerve terminals which type E toxin exploits to gain entry via an acidification-dependent step, whereas A uses only one...
  22. ncbi request reprint Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A
    Behzod Z Dolimbek
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Mol Immunol 44:1029-41. 2007
    ..The molecular and clinical implications of these findings are discussed...
  23. ncbi request reprint Botulinum toxin A in anal fissure: why does it work?
    Wolfgang H Jost
    Dis Colon Rectum 47:257-8. 2004
  24. ncbi request reprint A peptide-based immunoassay for antibodies against botulinum neurotoxin A
    M Zouhair Atassi
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    J Mol Recognit 20:15-21. 2007
    ....
  25. doi request reprint The binding sites on botulinum neurotoxin B for synaptotagmin and for blocking antibodies
    Behzod Z Dolimbek
    Biochem Biophys Res Commun 376:631-2. 2008
  26. doi request reprint Re: Botox produces functional weakness in non-injected muscles adjacent to the target muscle
    K Roger Aoki
    J Biomech 41:2066-7; author reply 2067. 2008
  27. doi request reprint Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics
    Jiafu Wang
    International Centre for Neurotherapeutics, Dublin City University, Glasnevin, Dublin 9, Ireland
    J Biol Chem 283:16993-7002. 2008
    ..AE produced the most persistent muscle weakening and therefore has therapeutic potential. Thus, proof of principle is provided for tailoring the pharmacological properties of these toxins by protein engineering...
  28. ncbi request reprint Molecular bases of protective immune responses against botulinum neurotoxin A--how antitoxin antibodies block its action
    M Zouhair Atassi
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Crit Rev Immunol 27:319-41. 2007
    ..Thus, analysis of the locations of the Ab-binding and the snp-binding regions provides a molecular rationale for the ability of protecting Abs to block BoNT/A action in vivo...
  29. pmc Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury
    Christopher P Smith
    Scott Department of Urology, Baylor College of Medicine, One Baylor Plaza, Alkek N720, Houston, TX 77030, USA
    Neurochem Int 52:1068-75. 2008
    ..e. ATP) and inhibitory (i.e. NO) urothelial transmitters promote bladder hyperactivity in rat bladders following SCI that can be reversed, to a large extent, by treatment with BoNT-A...
  30. ncbi request reprint Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin
    Behzod Z Dolimbek
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, United States
    Mol Immunol 45:910-24. 2008
    ..The regions thus localized afford candidates for incorporation into a synthetic vaccine design...
  31. ncbi request reprint Mapping of the synaptosome-binding regions on the heavy chain of botulinum neurotoxin A by synthetic overlapping peptides encompassing the entire chain
    Takahiro Maruta
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Protein J 23:539-52. 2004
    ..But some of the regions reside in the HN domain and might play a role in the translocation event...
  32. ncbi request reprint Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains
    Gulnoz S Dolimbek
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Immunol Invest 34:119-42. 2005
    ....
  33. ncbi request reprint Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: a new assay for blocking and non-blocking antibodies
    Takahiro Maruta
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    J Neurosci Methods 151:90-6. 2006
    ..Since the results with the toxoid were as discriminating as those of the active toxin, it would not even be necessary to use active toxin in these assays...
  34. ncbi request reprint Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A
    M Zouhair Atassi
    Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Mol Immunol 42:1509-20. 2005
    ..Protection was mostly associated with the immunoglobulin class of the antibodies. IgM antibodies were non-protective, while IgG Abs produced after the switch were protective...